Growth of infants fed formula supplemented with Bifidobacterium lactis Bb12 or Lactobacillus GG: a systematic review of randomized controlled trials

BMC Pediatrics

Anna Chmielewska¹  Hania Szajewska¹ 

[1] Department of Paediatrics, The Medical University of Warsaw, Dzialdowska 1, Warsaw 01-183, Poland

关键词: Children;    Infants;    Probiotics;    Growth;    Feeding;   

Others  :  1144318
DOI  :  10.1186/1471-2431-13-185

 received in 2013-08-14, accepted in 2013-10-31,  发布年份 2013

【 摘 要 】

Background

Growth is an essential outcome measure for evaluating the safety of any new ingredients, including probiotics, added to infant formulae. The aim of this systematic review was to determine the effects of supplementation of infant formulae with Bifidobacterium lactis Bb12 (B lactis) and/or Lactobacillus rhamnosus GG (LGG) compared with unsupplemented formula on the growth of healthy infants.

Methods

The MEDLINE, EMBASE, and Cochrane Library databases were searched in June 2013 for relevant randomized controlled trials (RCTs) conducted in healthy term infants. Unpublished data were obtained from the manufacturer of B lactis-supplemented formula. The primary outcome measures were weight, length, and head circumference.

Results

Nine eligible trials were identified. Compared with unsupplemented controls, supplementation of infant formula with B lactis had no effect on weight gain [4 RCTs, n = 266, mean difference (MD) 0.96 g/day, 95% confidence interval (CI) -0.70 to 2.63)], length gain (4 RCTs, n = 261, MD −0.39 mm/month, 95% CI −1.32 to 0.53), or head circumference gain (3 RCTs, n = 207, MD 0.56 mm/month, 95% CI −0.17 to 1.30). Data limited to one small (n = 105) trial suggest that infants who received standard infant formula supplemented with LGG grew significantly better. No such effect was observed in infants fed hydrolyzed formula supplemented with LGG.

Conclusions

Supplementation of infant formula with B lactis results in growth similar to what is found in infants fed unsupplemented formula. Limited data do not allow one to reach a conclusion regarding the effect of LGG supplementation on infant growth.

【 授权许可】

   
2013 Szajewska and Chmielewska; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Committee on the Evaluation of the Addition of Ingredients New to Infant Formula Infant Formula: Evaluating the Safety of New Ingredients. Washington, DC: The National Academies Press; 2004.
• [2]Braegger C, Chmielewska A, Decsi T, Kolacek S, Mihatsch W, Moreno L, Pieścik M, Puntis J, Shamir R, Szajewska H, Turck D, van Goudoever J, ESPGHAN Committee on Nutrition: Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr 2011, 52:238-250.
• [3]Weizman Z, Alsheikh A: Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents: a pilot study. J Am Coll Nutr 2006, 25:415-419.
• [4]Barclay D, Puccio G, Fazzolari-Nesci A, Giammanco A, Raiha N, Carrié-Fassler AL, Brown C, Chauffard Grathwohl D, Hager C, Haschke F, Endres W: Growth and tolerance of a whey-based starter infant formula with enhanced protein efficiency and containing pro-, pre or synbiotics. A randomized controlled trial in term infants [abstract]. J Pediatr Gastroenterol Nutr 2003, 37:388. [Abstract]
• [5]Urban MF, Bolton KD, Mokhachane M, Mphahlele RM, Bomela HN, Monaheng L, Beckh-Arnold E, Cooper PA: Growth of infants born to HIV-infected women, when fed a biologically acidified starter formula with and without probiotics. S Afr J Clin Nutr 2008, 21:28-32.
• [6]Higgins JPT, Altman DG: Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1. [updated September 2008]. Edited by Higgins JPT, Green S. Cochrane Collaboration; 2008. http://www.handbook.cochrane.org webcite
• [7]Gibson RA, Barclay D, Marshal H, Moulin J, Maire JC, Makrides M: Safety of supplementing infant formula with long chain polyunsaturated fatty acids and Bifidobacterium lactis in terms infants: a randomized controlled trial. Br J Nutr 2009, 101:1706-1713.
• [8]Holscher HD, Czerkies LA, Cekola P, Litov R, Benbow M, Santema S, Alexander DD, Perez V, Sun S, Saavedra JM, Tappenden KA: Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial. JPEN J Parenter Enteral Nutr 2012, 36(1 Suppl):106S-117S.
• [9]Velaphi SC, Cooper PA, Bolton KD, Mokhachane M, Mphahlele RM, Beckh-Arnold E, Monaheng L, Haschke-Becher E: Growth and metabolism of infants born to women infected with human immunodeficiency virus and fed acidified whey-adapted starter formulas. Nutrition 2008, 24:203-211.
• [10]Ziegler EE, Jeter JM, Drulis JM, Nelson SE, Haschke F, Steenhout P, Brown C, Maire JC, Hager C: Formula with reduced content of improved, partically hydrolyzed protein and probiotics: infant growth and health. Monatsschr Kinderheilkd 2003, 151:S65-S71.
• [11]Vendt N, Grünberg H, Tuure T, Malminiemi O, Wuolijoki E, Tillmann V, Sepp E, Korpela R: Growth during the first 6 months of life in infants using formula enriched with Lactobacillus rhamnosus GG: double-blind, randomized trial. J Hum Nutr Diet 2006, 19:51-58.
• [12]Scalabrin DM, Johnston WH, Hoffman DR, P’Pool VL, Harris CL, Mitmesser SH: Growth and tolerance of healthy term infants receiving hydrolyzed infant formulas supplemented with Lactobacillus rhamnosus GG: randomized, double-blind, controlled trial. Clin Pediatr (Phila) 2009, 48:734-744.
• [13]Rautava S, Arvilommi H, Isolauri E: Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res 2006, 60:221-224.
• [14]Rautava S, Salminen S, Isolauri E: Specific probiotics in reducing the risk of acute infections in infancy–a randomised, double-blind, placebo-controlled study. Br J Nutr 2009, 101:1722-1726.
• [15]Aggett PJ, Agostini C, Goulet O, Hernell O, Koletzko B, Lafeber HL, Michaelsen KF, Rigo J, Weaver LT, European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition: The nutritional and safety assessment of breast milk substitutes and other dietary products for infants: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2001, 32:256-258.
• [16]Mugambi MN, Musekiwa A, Lombard M, Young T, Blaauw R: Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review. Nutr J 2012, 11:81. BioMed Central Full Text
• [17]Chouraqui JP, Van Egroo LD, Fichot MC: Acidified milk formula supplemented with bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr 2004, 38:88-92.
• [18]Nopchinda S, Varavithya W, Phuapradit P, Sangchai R, Suthutvoravut U, Chantraruksa V, Haschke F: Effect of Bifidobacterium Bb12 with or without Streptococcus thermophilus supplemented formula on nutritional status. J Med Assoc Thai 2002, 85(Suppl 4):S1225-S1231.
• [19]Saavedra JM, Abi-Hanna A, Moore N, Yolken RH: Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr 2004, 79:261-267.
• [20]Weizman Z, Asli G, Alsheikh A: Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005, 115:5-9.
• [21]Koletzko B, von Kries R, Closa R, Escribano J, Scaglioni S, Giovannini M, Beyer J, Demmelmair H, Gruszfeld D, Dobrzanska A, Sengier A, Langhendries JP, Rolland Cachera MF, Grote V, European Childhood Obesity Trial Study Group: Lower protein in infant formula is associated with lower weight up to age 2 y: a randomized clinical trial. Am J Clin Nutr 2009, 89:1836-1845.
• [22]Koletzko B, Ashwell M, Beck B, Bronner A, Mathioudakis B: Characterisation of infant food modifications in the European Union. Ann Nutr Metab 2002, 46:231-242.